| 48.01 -0.94 (-1.92%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 63.61  |
1-year : | 68.28 |
| Resists | First : | 54.46 |
Second : | 58.45 |
| Pivot price | 52.83 |
|||
| Supports | First : | 48 |
Second : | 39.94 |
| MAs | MA(5) : | 49.61 |
MA(20) : | 53.84 |
| MA(100) : | 55.3  |
MA(250) : | 52.6 |
|
| MACD | MACD : | -2.1 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 0.7 |
D(3) : | 2.1 |
| RSI | RSI(14): 27 |
|||
| 52-week | High : | 62.45 | Low : | 40.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BIB ] has closed above bottom band by 4.7%. Bollinger Bands are 55.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 49.32 - 49.79 | 49.79 - 50.08 |
| Low: | 47 - 47.62 | 47.62 - 48 |
| Close: | 47.3 - 48.31 | 48.31 - 48.91 |
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Mon, 15 Apr 2024
How Has Shire Benefited from NPS Pharmaceuticals Acquisition? - Yahoo Movies Canada
Wed, 10 Apr 2024
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Sees Significant Decrease in Short Interest - MarketBeat
Mon, 25 Mar 2024
Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich - InvestorPlace
Mon, 11 Mar 2024
5 Small Biotech ETFs to Watch (Updated 2024) - Investing News Network
Mon, 11 Mar 2024
5 Small Biotech ETFs to Watch (Updated 2024) - Nasdaq
Thu, 22 Feb 2024
3 Biotech Stocks to Turn $10000 Into $1 Million: February 2024 - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|